관상 동맥 미세혈관 기능 장애의 비침습적 평가를 위한 혈관 활성 호흡 기동을 사용한 산소 민감성 심장 MRI

Executive Industry Relevance

Oxygenation-sensitive cardiac MRI with vasoactive breathing maneuvers enables non-invasive, quantitative assessment of coronary microvascular function, addressing a critical gap in early cardiovascular target validation. This approach eliminates the need for pharmacologic stress agents, supporting predictive confidence in disease-relevant systems and facilitating risk-adjusted portfolio decisions. Its vendor-agnostic implementation and endogenous contrast mechanism position it as a scalable, enterprise-ready capability for translational and preclinical research.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of coronary microvascular function in disease-relevant human models.
• Supports mechanistic de-risking by quantifying myocardial oxygenation dynamics without exogenous agents.
• Facilitates functional target validation in conditions such as INOCA and HFpEF.
• Provides predictive confidence for triaging cardiovascular targets in translational pipelines.

Screening & Assay Development

• Prepares validated, quantitative imaging assays for downstream compound evaluation.
• Standardizes assessment of myocardial oxygenation reserve (B-MORE) across cohorts.
• Enables reproducible, artifact-minimized imaging outputs for screening readiness.
• Supports scalable, vendor-agnostic deployment across imaging platforms.

Translational & Preclinical Research

• Aligns imaging biomarkers with disease-relevant endpoints in preclinical and clinical studies.
• Ensures continuity from early discovery through preclinical validation in microvascular dysfunction models.
• De-risks advancement decisions by providing quantitative, non-invasive readouts of vascular function.
• Facilitates integration with additional MR-based tissue and functional markers for comprehensive assessment.

Pipeline & Workflow Integration

This method integrates into the discovery-to-preclinical continuum, enabling hypothesis testing, quantitative imaging, and translational biomarker alignment for cardiovascular programs.

• Discovery Biology: Quantifies myocardial oxygenation changes in response to controlled physiological stimuli, supporting pathway clarification.
• Screening: Delivers standardized, reproducible B-MORE measurements for cross-cohort comparison.
• Analytics: Provides pixel-wise color overlay maps and quantitative outputs for robust statistical analysis.
• Translational Research: Bridges early discovery and preclinical validation with non-invasive, disease-relevant imaging biomarkers.
• Enterprise Reuse: Offers a vendor-agnostic, scalable imaging protocol adaptable across cardiovascular research portfolios.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in microvascular target validation.
• Operational Value: Standardizes imaging protocols, enhances reproducibility, and minimizes procedural risk.
• Strategic Value: Improves go/no-go decision quality and capital efficiency by providing robust, non-invasive endpoints.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of cardiovascular assets.

Implementation Considerations

• Requires expertise in cardiac MRI acquisition and physiological monitoring.
• Needs access to MRI scanners with modifiable SSFP sequences and respiratory monitoring infrastructure.
• Demands cross-team standardization of breathing maneuvers and imaging parameters.
• Adaptable across diverse patient populations and disease models with protocol adjustments.
• Dependent on artifact minimization and participant compliance for optimal data quality.

Biopharma FAQs